leisure time -WSS

leisure time

author：hotspot 2025-09-14 18:25:52 - browse：27693

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Cholera vaccine supply gets boost as demand surges globally

WSS

Cognito secures funding to test medical device for Alzheimer's

Close Medicare's dangerous gaps in addiction treatment coverage

Congressmen charge Covid hearing ‘could have been an email’

Cue Health's Covid

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

MultiPlan and major insurers sued for alleged medical price

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

What does generative AI mean for health care? We asked experts

After traumatic brain injury, life support decisions can use more time

What does generative AI mean for health care? We asked experts

Quicker fix for pulse oximeters urged during FDA public meeting

23andMe had bad news about my health. I wish a person had delivered it

What we need to know about Arena Bioworks

Peter Hotez and the public health issue of online harassment

Element Biosciences CEO lays out genome sequencing strategy

Psychedelics group wrestles with new pharma identity

Orangutan used medicinal plant to treat wound, first time ever seen

focus

ARCH Venture Partners is raising $3 billion for a life sciences fund

Cell therapy fails to slow type 1 diabetes, but safety is established

Close Medicare's dangerous gaps in addiction treatment coverage

Bird flu in milk supply is likely coming from asymptomatic cows

Novo Nordisk to expand supply of Wegovy for U.S. patients

After traumatic brain injury, life support decisions can use more time

focus

entertainment

leisure time

Wikipedia